1 week Ago By ABMN Staff
Vanguard Group Inc. trimmed its position in Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX – Free Report ) by 0.
1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,881,968 shares of the company’s stock after selling 5,006 shares during the quarter. Vanguard Group Inc.
owned approximately 0.06% of Syndax Pharmaceuticals worth $64,540,000 at the end of the most recent quarter. A number of other large investors also recently modified their holdings of the company.
Franklin Resources Inc. boosted its holdings in Syndax Pharmaceuticals by 13.4% in the 3rd quarter.
Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock valued at $34,948,000 after purchasing an additional 208,043 shares during the period. State Street Corp grew its position in Syndax Pharmaceuticals by 4.
1% during the third quarter. State Street Corp now owns 3,770,826 shares of the company’s stock worth $72,588,000 after buying an additional 148,491 shares in the last quarter. Barclays PLC increased its stake in Syndax Pharmaceuticals by 143.
4% in the 3rd quarter. Barclays PLC now owns 187,629 shares of the company’s stock worth $3,612,000 after acquiring an additional 110,535 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Syndax Pharmaceuticals by 3.
5% in the 3rd quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company’s stock valued at $38,066,000 after acquiring an additional 66,459 shares in the last quarter. Finally, Simplify Asset Management Inc.
boosted its position in shares of Syndax Pharmaceuticals by 20.8% during the 4th quarter. Simplify Asset Management Inc.
now owns 147,641 shares of the company’s stock valued at $1,952,000 after acquiring an additional 25,456 shares during the last quarter. Syndax Pharmaceuticals Stock Performance Shares of Syndax Pharmaceuticals stock opened at $10.52 on Friday.
Syndax Pharmaceuticals, Inc. has a 52-week low of $9.66 and a 52-week high of $25.
07. The company’s 50 day moving average price is $13.73 and its 200-day moving average price is $15.
38. The stock has a market capitalization of $905.18 million, a price-to-earnings ratio of -2.
90 and a beta of 1.28. Wall Street Analysts Forecast Growth SNDX has been the topic of a number of recent analyst reports.
StockNews.com raised shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Thursday. Citigroup lowered their price objective on shares of Syndax Pharmaceuticals from $45.
00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. JPMorgan Chase & Co.
increased their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, March 20th.
Scotiabank dropped their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th.
Finally, HC Wainwright reissued a “buy” rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock.
Based on data from MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $36.20.
Get Our Latest Report on SNDX Insider Activity at Syndax Pharmaceuticals In other Syndax Pharmaceuticals news, insider Neil Gallagher sold 4,618 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $71,579.
00. Following the transaction, the insider now directly owns 85,095 shares of the company’s stock, valued at approximately $1,318,972.50.
The trade was a 5.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website .
Also, CEO Michael A. Metzger sold 13,288 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.
50, for a total transaction of $205,964.00. Following the completion of the sale, the chief executive officer now directly owns 300,121 shares of the company’s stock, valued at approximately $4,651,875.
50. This represents a 4.24 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Insiders have sold a total of 21,683 shares of company stock worth $336,087 in the last 90 days. Company insiders own 4.
10% of the company’s stock. About Syndax Pharmaceuticals ( Free Report ) Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Featured Stories Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX – Free Report ).
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
